Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Harpoon Therapeutics, Inc. - Common Stock
(NQ:
HARP
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Mar 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Harpoon Therapeutics, Inc. - Common Stock
< Previous
1
2
Next >
Harpoon Therapeutics Inc. (NASDAQ: HARP) Records 52-Week High Thursday Morning
February 22, 2024
Via
Investor Brand Network
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
January 16, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
HARPOON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Harpoon Therapeutics, Inc. - HARP
January 10, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
January 08, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Harpoon Therapeutics Inc. (NASDAQ: HARP) Near the Top of Equities by Percentage Gain on 1/8
January 08, 2024
Via
Investor Brand Network
Merck, the Dow's hottest stock, gets set to report Q4 financials
January 08, 2024
Up 5.7% year-to-date, pharmaceuticals - including MRK - are the best performing industry in the entire U.S. equity market, outpacing even biotech stocks.
Via
MarketBeat
Topics
Stocks
HARP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Harpoon Therapeutics, Inc. Is Fair to Shareholders
January 08, 2024
From
Halper Sadeh LLC
Via
Business Wire
Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline
January 08, 2024
From
Merck & Co., Inc.
Via
Business Wire
Harpoon Therapeutics Strengthens Leadership Team
December 26, 2023
From
Harpoon Therapeutics Inc.
Via
GlobeNewswire
Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium
December 19, 2023
From
Harpoon Therapeutics Inc.
Via
GlobeNewswire
Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)
December 11, 2023
From
Harpoon Therapeutics Inc.
Via
GlobeNewswire
Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 09, 2023
From
Harpoon Therapeutics Inc.
Via
GlobeNewswire
Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
November 02, 2023
From
Harpoon Therapeutics Inc.
Via
GlobeNewswire
Harpoon Therapeutics Announces Up to $150 Million Private Placement
October 23, 2023
From
Harpoon Therapeutics Inc.
Via
GlobeNewswire
Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
October 21, 2023
From
Harpoon Therapeutics Inc.
Via
GlobeNewswire
Harpoon Therapeutics Inc. (NASDAQ: HARP) Leading the Way in Wednesday Trading Based on Percentage Gain
October 18, 2023
Via
Investor Brand Network
Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023
October 16, 2023
From
Harpoon Therapeutics Inc.
Via
GlobeNewswire
Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
October 09, 2023
From
Harpoon Therapeutics Inc.
Via
GlobeNewswire
Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual Meeting
September 28, 2023
From
Harpoon Therapeutics Inc.
Via
GlobeNewswire
Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort
September 15, 2023
From
Harpoon Therapeutics Inc.
Via
GlobeNewswire
Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie
September 13, 2023
From
Harpoon Therapeutics Inc.
Via
GlobeNewswire
Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting
September 06, 2023
From
Harpoon Therapeutics Inc.
Via
GlobeNewswire
Harpoon Therapeutics to Host KOL Event in Person and via Webcast on September 15, 2023
September 05, 2023
From
Harpoon Therapeutics Inc.
Via
GlobeNewswire
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in September
September 05, 2023
From
Harpoon Therapeutics Inc.
Via
GlobeNewswire
Harpoon Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 09, 2023
From
Harpoon Therapeutics Inc.
Via
GlobeNewswire
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in August
August 03, 2023
From
Harpoon Therapeutics Inc.
Via
GlobeNewswire
Harpoon Therapeutics Appoints Haibo Wang as Senior Vice President of Business Development
August 01, 2023
From
Harpoon Therapeutics Inc.
Via
GlobeNewswire
Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma
June 27, 2023
From
Harpoon Therapeutics
Via
GlobeNewswire
Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023
From
Harpoon Therapeutics
Via
GlobeNewswire
Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023
April 18, 2023
From
Harpoon Therapeutics
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
